An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A new article compared two types of diabetes drugs to see how they affect people with heart failure. The piece looked at existing studies and clinical findings to weigh SGLT2 inhibitors against GLP-1 receptor agonists for patients who have or are at risk for heart failure. It’s not a single trial that suddenly changes practice, but a review and comparison of what researchers have learned so far. SGLT2 inhibitors are pills that were developed to help lower blood sugar by making the kidneys flush extra sugar into the urine. But doctors noticed they also help the heart in ways beyond lowering blood sugar — for example, by reducing fluid overload and easing stress on the heart. GLP-1 receptor agonists are different drugs (often injections) that copy a natural gut hormone that slows the stomach and tells the brain you’re full. They’re primarily used to lower blood sugar and help people lose weight, and researchers have also studied whether they protect the heart. What the comparison shows is that SGLT2 inhibitors have clearer, more consistent benefits for people with heart failure. Large clinical trials in thousands of patients found these drugs lower the risk of hospitalization for heart failure and may improve outcomes even for people who don’t have diabetes. Evidence for GLP-1 receptor agonists is more mixed: some studies hint they reduce certain cardiovascular events, and they help with weight and blood sugar, but they haven’t shown the same strong, consistent benefit specifically for heart failure outcomes. Much of the SGLT2 evidence comes from big randomized trials. The GLP-1 evidence comes from a mix of trials and analyses where the heart-failure signal is weaker or inconsistent. Why this matters is practical. If someone has heart failure — or is at high risk for it — clinicians may favor adding an SGLT2 inhibitor because the drug class has reliable trial evidence of reducing hospitalizations and improving heart-related outcomes. People with obesity and diabetes who want weight loss and improvement in blood sugar might still benefit from GLP-1 drugs, but those aren’t the first-line option purely for treating heart failure. For patients and families, this information helps frame conversations with doctors about which medications will most likely protect the heart, not just lower blood sugar. There are important caveats. These drugs are prescription medicines with side effects and costs. SGLT2 inhibitors can increase the risk of urinary tract and genital infections and can cause volume depletion (feeling faint or dehydrated); they’re not suitable for everyone. GLP-1 receptor agonists commonly cause nausea and can be expensive; their long-term effects on heart failure specifically remain less certain. Regulatory approvals differ by country and by indication, so doctors prescribe based on individual patient factors and current guidelines. The review doesn’t invent new data; it summarizes existing trials and their limits. Bottom line: for heart failure specifically, the trial evidence favors SGLT2 inhibitors over GLP-1 receptor agonists, but treatment choice should be individualized and discussed with a clinician.
Source: AJMC